Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the ...

Natera (NTRA) commented on recent updates by the NCCN on circulating tumor DNA molecular residual disease testing in the Clinical Practice ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the ...

Investing.com -- AIM ImmunoTech Inc. (NYSE American: AIM) a annoncé son intention de développer Ampligen comme adjuvant vaccinal contre la grippe aviaire. Cette initiative s'inscrit dans le cadre de ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.

Allied Physicians Group, New York's largest independent pediatric care provider with over 38 offices, and Adjuvant.Health, ...

The breakthrough centers on a new class of materials called lipopeptide hydrogels (LPHs), which show promise in boosting immune responses and possess adjuvant-like properties. "Traditional peptide ...

Natera, Inc. a commenté les récentes mises à jour du NCCN sur l'ADN tumoral circulant et le test de la maladie moléculaire résiduelle dans les lignes directrices de pratique clinique ...